AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE

Stroke Clinical Trial

— APPENDAGE  

Official title:

AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04796714
• Other study ID #: CHUBX 2017/29
• Status: Recruiting
• Phase: Phase 4
• Start date: October 3, 2022
• Est. completion date: May 3, 2024

Study information

• Verified date: October 2022
• Source: University Hospital, Bordeaux
• Contact: Zakaria JALAL, MD
• Phone: (0)5 57 65 64 65
• Email: zakaria.jalal[@]chu-bordeaux.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF). The primary objective of the study is to evaluate the efficacy of Aspirin versus Aspirin + Clopidogrel after LAAC by comparing the occurrence of ischemic lesions on cerebrovascular magnetic resonance imaging (MRI) studies.

Description:

Atrial fibrillation (AF) is the most common sustained arrhythmia and increases the risk of ischemic stroke. Although oral anticoagulation (OAC) is recommended in patients with CHADS2VA2SC score ≥ 1, this medication is associated with severe haemorrhagic complications. Several trials showed that percutaneous LAAC with the Watchman device (Boston Scientific, Natick, Massachusetts) or the Amplatzer Cardiac Plug (ACP) /Amulet device (St. Jude Medical, Minneapolis, Minnesota) was shown to be non-inferior but also superior as compared to warfarin in preventing the combined outcome of stroke, systemic embolism, and cardiovascular death. Therefore, LAAC has become an integral part of treatment guidelines in AF patients.

However, the post procedural management of antithrombotic therapy in these patients remains a challenge, as bleeding risk needs to be balanced against risk for thrombus formation on the device and thromboembolic complications. After LAAC, various antithrombotic protocols have been proposed by different teams but the optimal postprocedural antithrombotic medication and its duration are still debated. The Investigators recently showed in a prospective registry that LAAC using ACP devices followed by a single antiplatelet therapy could be a reasonable alternative for stroke prevention in patients with high bleeding risk.

The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies (aspirin versus aspirin + clopidogrel) following LAAC. The primary objective of the study is to evaluate the efficacy of these 2 strategies after LAAC by comparing the occurrence of ischemic lesions on cerebrovascular MRI studies performed immediately after the procedure (D 0) and after 3 months of follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: May 3, 2024
• Est. primary completion date: May 3, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients with LAAC indication according to "Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé" (CNEDiMTS) (National Commission for the Evaluation of Medical Devices and Health Technologies) guidelines

• Age = 18 years

• Written informed consent provided by the patient

• Heart team approval: multidisciplinary team including interventional cardiologists, neurologists and other physicians discussing the definitive contraindication for anticoagulation

• Registration under social security system

Exclusion Criteria:

• Minors

• Unacceptable bleeding risk with double antiplatelet therapy decided by the physician who contraindicated oral anticoagulation

• LAAC contraindication : left appendage thrombus

• Major disease resulting in a life expectancy of < 1 year

• Severe and inherited bleeding disorder

• Known hypersensitivity to aspirin and/or clopidogrel:

• Hypersensitivity to clopidogrel, acetylsalicylic acid, or one of the excipients or other nonsteroidal anti-inflammatory drugs (cross-reaction).

• Asthma or a history of asthma with or without nasal polyps induced by salicylates or substances of close activity, including nonsteroidal anti-inflammatory drugs.

• Evolving peptic ulcer or history of gastric hemorrhage or perforation after treatment with acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.

• Any constitutional or acquired haemorrhagic disease.

• Patients with mastocytosis, in whom the use of acetylsalicylic acid can lead to severe hypersensitivity reactions (including circulatory shocks with flushing, hypotension, tachycardia and vomiting).

• Severe liver failure.

• Severe kidney failure (Creatinine light < 30ml/min).

• Uncontrolled severe heart failure

• Contraindication to MRI: claustrophobia or inability to lie still for exam time, implantable pacemaker or defibrillator, intracorporeal metal foreign body (especially intraocular), intracranial metal clip, cochlear implant, cardiac valve prosthesis type Starr-Edwards pre 6000, or biomedical device type insulin pump or neurostimulator.

• Guardianship

• Curatorship

• Pregnancy or child-bearing potential female

• Woman of childbearing age who does not benefit from highly effective contraception (CTFG recommendation on highly effective contraceptive methods: oral, intravaginal or transdermal estrogeno-progestin contraception; progestin-based oral, injectable or implantable contraception; intrauterine device; hormonal intrauterine device; female sterilization (occlusion of the fallopian tubes))

• Iode contraindication

• Patient already participating in another category 1 interventional research

• Patient in a period of exclusion relative to another research protocol.

Related Conditions & MeSH terms

• Anticoagulants
• Atrial Appendage
• Atrial Fibrillation
• Platelet Aggregation Inhibitors
• Stroke

Intervention

Drug:
• Double antiplatelet therapy
One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
• Aspirin
One sachet of aspirin 160 mg per day during 3 months

Device:
• Brain MRI
Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).

Other:
• Neurological tests
Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)

Locations

Country	Name	City	State
France	Bordeaux University Hospital	Pessac
France	Toulouse University Hospital	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline of ischaemic lesions number at 3 months appearing on brain MRI scans	Assessment of number of ischaemic lesions appearing on diffusion sequences and/or (Fluid Attenuated Inversion Recovery) FLAIR between cerebral MRI scans at D0 after implantation and after 3 months of antithrombotic treatment. The interpretation of the MRI scans will be centralised and carried out by an independent Corelab in the neuro radiology imaging department of Bordeaux University Hospital. These analyses will be carried out by two independent radiologists. In the event of disagreements or inconsistent values, a third review will be carried out by a third independent radiologist. The final value of the different variables will be reduced to the average of these 2 or 3 interpretations.	Baseline and 3 months
Secondary	Occurrence of symptomatic cerebral ischaemic events	Number of cerebral infarctions and transient ischaemic attacks identified by MRI and systematic neurological examination at D1 and M3, and at any time in the event of a symptomatic event.	From day 1 to month 3
Secondary	Occurrence of systemic thromboembolic events	Number of systemic thromboembolic events that will be identified when clinically symptomatic	From day 1 to month 3
Secondary	Occurrence of cerebral haemorrhagic events	Number of cerebral haemorrhagic events that will be identified by MRI and by systematic neurological examination at D0 and M3, and at any time in the event of a symptomatic event	From day 0 to month 3
Secondary	Occurence of systemic bleeding events	Number of systemic bleeding events that will be identified when clinically symptomatic	From day 1 to month 3
Secondary	Assessment by the NIHSS scale (National Institute of Health Stroke Score) of the functional impact of ischaemic and/or haemorrhagic strokes	It will be measured by the NIHSS scale score. Values range from 0 to 42. Score 1 to 4: minor stroke, 5 to 15 : moderate stroke, 15 to 20 : severe stroke, > 20 : severe stroke	Day 1 and month 3
Secondary	Assessment by the Modified Rankin Score of the functional impact of ischaemic and/or haemorrhagic strokes	It will be measured by the Modified Rankin Score. Values range from 0 (no symptoms) to 5 (severe disability)	Day 1 and month 3
Secondary	Cognitive assessment by the Montreal Cognitive Assessment (MoCA) scale	Patients cognitive assessment will be performed using the Montreal Cognitive Assessment (MoCA) scale score. Values range from 0 to 30. A score of 26 is considered normal.	Day 1 and Month 3
Secondary	Occurrence of procedural related complications	The number of procedural related complications (device embolization, significant pericardial effusion) will be assessed by physical examination and transthoracic echocardiography	From day 0 to month 3
Secondary	Occurence of device-related thrombus, persistence of a residual leak and endothelialisation process	The number of device-related thrombus, persistence of a residual leak and endothelialisation process will be assessed by cardiac computed tomography (CT)	Month 3
Secondary	Counting of treatments taken	Compliance will be assessed for all patients by counting the number of treatments taken versus those that should have been taken. This compliance will be correlated with thromboembolic and hemorrhagic events to define the imputability of the therapeutic strategy on these events.	Month 3